Findings showed a noninferior immune response for both vaccines when coadministered compared with separate administration. Topline results were announced from a phase 3 study assessing the immune ...
Arexvy is a brand-name respiratory syncytial virus (RSV) vaccine. It’s used in some adults to help prevent lung disease from RSV. Arexvy should not be used during pregnancy and breastfeeding ...
(RTTNews) - GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY when co ...
Specifically, the FDA recently approved Arexvy, the world’s first vaccine to fight RSV in adults aged 60 and older. According to its manufacturer GSK, the single shot provides long-term ...
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
The company studied co-administration of its RSV vaccine Arexvy and Shingrix in a phase 3 study of 530 adults age 50 years and older. When the shots were given during the same doctor's visit ...
Window insulation kits offer an affordable way to cut the cost of your energy bill and make a home less drafty. For those who cannot afford to replace windows, a window insulation kit is a great ...
Historically, the British drugmaker’s R&D returns were dominated by its HIV treatments and Shingrix and Arexvy vaccines, they say. Shares are down 0.9%. ([email protected]) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback